Starpharma Holdings Ltd has released a press release.
AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Annual report and full year financial results
- VivaGel BV NDA advances to next stage of FDA review
- Starpharma licenses VivaGel BV to Mundipharma for Europe
- Mundipharma licenses Starpharmas VivaGel BV
- Appendix 4C - Quarterly Cashflow Report
Later from Starpharma
- DEP irinotecan outperforms in pancreatic cancer model
- Starpharma Investor Presentation for Citi Conference
- DEP products outperform in human pancreatic cancer model
- US VivaGel BV licensed for A$142M milestones plus royalties
- US FDA requests further data for VivaGel BV approval
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma